Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luvi: Lucentis and Visudyne Combination in Neovascular AMD
NCT00574093Phase 2Completed
- Sponsor
- Fondazione G.B. Bietti-IRCCS
- Start
- Jan 2008
- Primary completion
- Jun 2009
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ranibizumab, verteporfin in neovascular age-related macular degeneration (NVAMD), sponsored by Fondazione G.B. Bietti-IRCCS. Started Jan 2008; status: completed.
02
Drugs
ranibizumabverteporfin
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00574093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00574093.